STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR's lens used in refractive surgery is called an Implantable Collamer® Lens or 'ICL', which includes the EVO Visian ICL™ product line. More than 1,000,000 Visian® ICLs have been implanted to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: www.discovericl.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland.

Company profile
Ticker
STAA
Exchange
Website
CEO
Caren Mason
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
STAAR SURGICAL COMPANY
SEC CIK
Corporate docs
Subsidiaries
STAAR Surgical UK LTD • STAAR Surgical AG • STAAR Japan Inc. • STAAR Surgical PTE. LTD • Technology (Shanghai) Co., LTD • CO., LTD • STAAR Surgical India Private Limited ...
IRS number
953797439
STAA stock data
Analyst ratings and price targets
Current price
Average target
$77.17
Low target
$60.00
High target
$85.00
Benchmark
Maintains
$75.00
Canaccord Genuity
Maintains
$80.00
Stephens & Co.
Maintains
$85.00
Stifel
Initiated
$60.00
Latest filings (excl ownership)
8-K
Amendments to Articles of Incorporation or Bylaws
1 Feb 23
8-K
STAAR Surgical Reports Preliminary Sales for Fourth Quarter and Fiscal 2022
9 Jan 23
8-K
STAAR Surgical CEO Caren Mason to Retire; Tom Frinzi Appointed New CEO
19 Dec 22
8-K
STAA.OQ - Q3 2022 STAAR Surgical Co Earnings Call
3 Nov 22
10-Q
2022 Q3
Quarterly report
2 Nov 22
8-K
STAAR Surgical Reports Third Quarter Net Sales of $76 Million Up 30% Y/Y
2 Nov 22
8-K
Regulation FD Disclosure
11 Aug 22
10-Q
2022 Q2
Quarterly report
10 Aug 22
8-K
STAAR Surgical Reports Record Second Quarter Net Sales of $81.1 Million Up 30% Y/Y
10 Aug 22
8-K
Departure of Directors or Certain Officers
20 Jul 22
Transcripts
STAA
Earnings call transcript
2022 Q2
11 Aug 22
STAA
Earnings call transcript
2022 Q1
4 May 22
STAA
Earnings call transcript
2021 Q4
24 Feb 22
STAA
Earnings call transcript
2021 Q3
4 Nov 21
STAA
Earnings call transcript
2021 Q2
5 Aug 21
STAA
Earnings call transcript
2021 Q1
6 May 21
STAA
Earnings call transcript
2020 Q4
25 Feb 21
STAA
Earnings call transcript
2020 Q3
4 Nov 20
STAA
Earnings call transcript
2020 Q3
4 Nov 20
STAA
Earnings call transcript
2020 Q2
5 Aug 20
Latest ownership filings
Financial summary
Quarter (USD) | Sep 22 | Jul 22 | Apr 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Jan 21 | Jan 20 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 129.24 mm | 129.24 mm | 129.24 mm | 129.24 mm | 129.24 mm | 129.24 mm |
Cash burn (monthly) | 24.42 mm | 5.58 mm | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 100.81 mm | 23.05 mm | n/a | n/a | n/a | n/a |
Cash remaining | 28.43 mm | 106.19 mm | n/a | n/a | n/a | n/a |
Runway (months of cash) | 1.2 | 19.0 | n/a | n/a | n/a | n/a |
Institutional ownership, Q3 2022
13F holders | Current |
---|---|
Total holders | 293 |
Opened positions | 53 |
Closed positions | 25 |
Increased positions | 104 |
Reduced positions | 99 |
13F shares | Current |
---|---|
Total value | 7.82 bn |
Total shares | 54.07 mm |
Total puts | 415.40 k |
Total calls | 928.30 k |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
Broadwood Partners | 8.59 mm | $0.00 |
Broadwood Capital | 8.59 mm | $606.17 mm |
BLK Blackrock | 5.60 mm | $394.83 mm |
Vanguard | 5.22 mm | $368.16 mm |
Baillie Gifford & Co | 5.13 mm | $361.77 mm |
Palo Alto Investors | 1.10 mm | $77.39 mm |
Geneva Capital Management | 947.13 k | $66.82 mm |
Geode Capital Management | 870.93 k | $61.44 mm |
E Fund Management | 732.30 k | $51.66 mm |
PFG Principal Financial Group Inc - Registered Shares | 693.12 k | $48.90 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
3 Jan 23 | Frinzi Thomas G | Common Shares | Option exercise | Acquire M | No | No | 0 | 87,805 | 0.00 | 92,534 |
3 Jan 23 | Frinzi Thomas G | Common Stock Options Common Stock | Option exercise | Acquire M | No | No | 51.25 | 160,638 | 8.23 mm | 160,638 |
30 Dec 22 | James E Francese | Common Stock Options Common Stock | Option exercise | Acquire M | No | No | 48.54 | 19,139 | 929.01 k | 19,139 |
29 Dec 22 | Broadwood Partners | Common Stock | Buy | Acquire P | Yes | No | 0 | 0 | 0.00 | 8,783,082 |
29 Dec 22 | Broadwood Partners | Common Stock | Buy | Acquire P | No | No | 47.9261 | 39,090 | 1.87 mm | 8,783,082 |
28 Dec 22 | Broadwood Partners | Common Stock | Buy | Acquire P | Yes | No | 0 | 0 | 0.00 | 8,743,992 |
28 Dec 22 | Broadwood Partners | Common Stock | Buy | Acquire P | No | No | 46.9761 | 100,000 | 4.70 mm | 8,743,992 |
27 Dec 22 | Broadwood Partners | Common Stock | Buy | Acquire P | Yes | No | 0 | 0 | 0.00 | 8,643,992 |
27 Dec 22 | Broadwood Partners | Common Stock | Buy | Acquire P | No | No | 47.9087 | 51,985 | 2.49 mm | 8,643,992 |
27 Sep 22 | James E Francese | Common Stock | Sell | Dispose S | No | No | 75 | 13,075 | 980.63 k | 34,908 |
News
Benchmark Maintains Buy on Staar Surgical, Lowers Price Target to $75
1 Feb 23
Canaccord Genuity Maintains Buy on Staar Surgical, Raises Price Target to $80
30 Jan 23
Analyst Reiterates This Ophthalmology Device Stock On Steep But Attractive Risk/Reward
24 Jan 23
Analyst Expectations for Staar Surgical's Future
20 Jan 23
Canaccord Genuity Maintains Buy on Staar Surgical, Raises Price Target to $79
20 Jan 23